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New anticoagulants and regional anaesthesia
in patients undergoing orthopedic surgery
Abstract
Background and Purpose: there are many advantages of regional ana-
esthesia for orthopedic procedures. In perioperative period orthopedic pa-
tients received thromboprophylaxis with low mollecular weight heparins
(LMWH) or new anticoagulated drugs. The most popular new drugs for
thromboprophylaxis in patients with joint replacement are fondaparinux,
rivaroxaban and dabigatran. After introduction of LMWH for throm-
boprophylaxis serious complications including spinal hematoma have been
reported. It is very important perform regional anaesthesia in patients re-
ceiving anticoagulated drugs according to recommendations. These article
reviews the actual recommendations and the current status and manage-
ment of these new drugs.
Recent findings: recent studies are outlined that the risk of spinal
hematoma after neuraxial anaesthesia may be higher than estimated. The
use of new anticoagulant drugs should take into account the pharmacologi-
cal profile of each drug to safely perform regional anaesthesia, mainly the
time to reach peak plasma level and half-life.
Conclusion: When new anticoagulant drugs are used for thrombopro-
phylaxis in orthopedic surgery, the performance of neuraxial anaesthesia is
safe method if is based on the pharmacology of drugs. All methods of re-
gional anaesthesia should be perfomed according to accepted recommenda-
tions regarding the time of block and the time of drug administration.
INTRODUCTION
Regional anaesthesia and analgesia are widely used in perioperativetreatment of orthopedic patients. There are many advantages of
spinal or epidural analgesia/anaesthesia over general anaesthesia in pa-
tients undergoing orthopedic surgery including reduced postoperative
cardiovascular and pulmonary complications, blood loss and need for
transfusion and decreased incidence of thromboembolic complica-
tions. Many studies confirmed reduction in perioperative mortality and
morbidity including reduction in incidence of thromboembolic compli-
cations if operative procedures are performed under regional anaesthe-
sia. A meta analysis of randomized trials revealed that the use of pe-
rioperative regional anaesthesia can decrease mortality by approxi-
mately 30 %, deep venous thrombosis by 44 %, pulmonary embolism by
55 %, respiratory depression by 59 % and the need for transfusion by 55 %.
The rationale for thromboprophylaxis is based on the high preva-
lence of venous thromboembolism among hospitalised patients. The
highest incidence of thromboembolic complications is among ortho-
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paedic patients scheduled for total joint replacement sur-
gery. Without thromboprophylaxis the prevalence of deep
venous thrombosis is over 50 % after total knee or hip re-
placement surgery. The incidence of calf deep venous
thrombosis (DVT) is 40% to 80%, proximal DVT 10% to
20%, clinical pulmonary embolism (PE) 4% to 10%, fatal
PE 0.2% to 5%. However, the high incidence of throm-
boembolic complications is confirmed after general sur-
gery procedures, after urologic, gynecologic and trauma
surgery. In many patients, multiple risk factors are pres-
ent, and the risks are cumulative. Formal risk assesment
models for DVT or PE have been proposed for surgical
patients. According to risk assesment models the prophy-
laxis recommendations are used in perioperative treat-
ment. In a random survey of fellows of the American
College of Surgeons, 86 % claimed they used prophylaxis
in 1993, this proportion rising to 96 % by 1997.
Improvement in patient outcomes when regional ana-
esthesia techniques are used is due to the attenuation of
the hypercoagulable response and the associated reduc-
tion in the frequency of thromboembolism. However
this effect is insufficient as the sole method of thrombo-
prophylaxis. In orthopedic patients thromboprophylaxis
should be administered perioperatively. There are many
recommendations how to perform thromboprophylaxis.
The most popular are ACCP (American College of Chest
Phycians) recommendations, but there are also ESA (Eu-
ropena Society of Anaesthesia) recommendations and
national recommendations. For example, the initial rec-
ommendations were presented in 1986 by ACCP stated
that patients undergoing hip or knee arrhoplasty receive
dextran, adjusted dose standard heparin (approximately
3500 U every 8 hours), warfarin (started 48 hours preop-
eratively to achieve a prothrombin time (PT) 1.25–1.5
times baseline), or dextran plus intermittent pneumatic
compression. The duration of thromboprophylaxis is
continued after hospital discharge for a total of 10 to 35
days.
The ACCP guidelines are widely recognized as a
practice standard for VTE prevention and treatment,
and have been regularly updated throughout recent de-
cades. The most recent version, issued in 2009, is for-
mally known as the 8th ACCP Conference on Antithrom-
botic and Thrombolytic Therapy.
The combination of regional anaesthesia and throm-
bopropylaxis is standard for many operative procedures.
Unfortunately serious complications like perispinal he-
matoma can occur after spinal or epidural anaesthesia
performed in patients receiving thromboprophylaxis. Al-
though rare, the seriousness of this complication man-
dates very cautious use of antithrombotic medications in
patients having neuraxial blockade. In a review of the lit-
erature between 1906 and 1994 year 61 cases of spinal
hematoma associated with epidural or spinal anaesthesia
have been reported. Great importance of spinal hema-
toma was recognised after approval of LMWH for clini-
cal use. LMWH heparins are in use in Europe from 1989
and in USA from 1993. In 1997, only 4 years after the re-
lease of LMWH for general use in USA in May 1993, a
series of 43 patients who had developed perispinal he-
matoma after receiving the LMWH enoxaparin concur-
rently with spinal or epidural anaesthesia have been repor-
ted. Many of these patients suffered neurologic impair-
ment, including permanent paralysis, despite decompre-
ssive laminectomy. The median age was 78 years (28–90),
and 78 % of patients were women. Concomitant antipla-
telet therapy was present in several cases. Nearly 90% of
these complications occured in patients receiving enoxa-
parin as prophylaxis after primarily total knee or hip re-
placement. Many of these events occurred when LMWH
was administered intraoperatively or early postopera-
tively to patients undergoing continuous epidural anaes-
thesia and analgesia. At same time 10 cases of spinal
hematoma have been reported in Europe. The possible
explanation for this apparent difference in incidence in
Europe may be a result of a difference in dose and dose
schedule. For example, in Europe the recommended
dose of enoxaparin is 40 mg once daily initiated 12 hours
preoperatively while in USA is 30 mg twice daily. The
predisposing factors also include the presence of an un-
derlying hemostatic disorder, traumatic needle or cathe-
ter insertion, repeated insertion attempts or blood return,
time of catheter insertion or removal, use of continuous
epidural catheters, administration of medications known
to increase bleeding. Manufacturers of LMWHs subse-
quently added a boxed warning to the prescribing infor-
mation, alerting clinicians to this potential effect. How-
ever, it became clear that at least some of these outcomes
resulted from lack of attention to timing of the neuraxial
anaesthesia relative to the dose of LMWH, traumatic
needle placement, and catheter removal during thera-
peutic levels of anticoagulation.
In response to these serious complications the Ameri-
can Society of Regional Anaesthesia and Pain Medicine
(ASRA) held three Consensus Conferences on Regional
Anaesthesia and Anticoagulation where recommendations
how to perform regional anaesthesia in patients receiv-
ing anticoagulation drugs were achieved. These recom-
mendations were published in the Journal of Regional
Anaesthesia and Pain Medicine.
In last two decades new antithrombotic drugs are in-
troduced for thromboprophylaxis in orthopedic patients
and there is question how to perform regional anaesthe-
sia procedures with concommitant use of antithrombotic
drugs in order to avoid serious bleeding complications.
New anticoagulants
Because of great importance of thromboprophylaxis
anticoagulated drugs are under permanent investigation.
All new drugs have focused their developement on trying
to posses the characteristics of the ideal anticoagulant.
These characteristics include: possibility of oral (one tab-
let, once daily) and parenteral (once daily) adminstra-
tion, high effectivity in reducing thromboembolic events,
low rate of complications (focus on bleeding), possibility
of reversal, predictable pharmacokinetics, predictable dose
response, rapid onset of action, no need for routine mon-
itoring, wide therapeutic window, no dose adjustment
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required, no interaction with other drugs and inhibition
of both free and clot-bound activated coagulation factors.
Of course no licensed medication has all these properties.
New antithrombotic drugs that target various steps in
the hemostatic system with many of these properties are
continuallly under development. The most extensivelly
studied are direct Factor X and thrombin inhibitors.
Many of these agents have prolonged half-lives and are
difficult to reverse without administration of blood com-
ponents. In last decade three new anticoagulation drugs
are licensed for thromboprophylaxis in orthopedic sur-
gery. There are two Factor X selective inhibitors (paren-
terally administered Fondaparinux and perorally admini-
stered Rivaroxaban) and Dabigatran, new direct throm-
bin inhibitor given perorally. After serious complications
reported with introduction of LMWH in clinical use spe-
cial caution is given to regional aneshesia and these
drugs. The administration of these drugs in combination
with regional anaesthesia must be carefully considered.
Importantly, until large series become available, we can
apply lessons learned from LMWH experience to de-
velop initial management recommendations.
Central nerve blocks and new
anticoagulants
Current recommendations on the use of anticoagu-
lants with neuraxial anaesthesia are based on drug-spe-
cific pharmacodynamics. All guidelines focus on safety
according to the delay between the last dose of anticoag-
ulant and catheter withdrawal, but may underestimate
the risk of bleeding associated with the next dose if they
allow only a very short delay between catheter removal
and the next dose of anticoagulant. However, there is a
risk of vessel injury when the catheter is removed, and
hence the risk of bleeding remains after the next dose of
anticoagulant if the delay is too short. An alternative sug-
gestion for managing epidural catheters or spinal needles
in the setting of anticoagulation has been put forward,
taking into account both of the safety delays between
catheter withdrawal and the last dose of anticoagulant,
and between catheter removal and the next dose. This
suggestion has the advantage that it is based on the
drug-specific pharmacology of the anticoagulant being
used, particularly the elimination half-life, and time to
reach maximum anticoagulant activity. This has been
used rather than Tmax (time to reach maximum plasma
concentration) as it is the drug’s pharmacodynamic pro-
file, rather than its phormacokinetics, which directly af-
fects anticoagulant activity. Furthermore, this allows the
suggestion to be applied to all anticoagulants, including
those in which the pharmacodynamics and pharmaco-
kinetics are not temporally correlated. This suggestion
could provide a universally applicable method of esti-
mating when to remove the neuraxial needle or catheter
and when to restart anticoagulation. With performing
central nerve blocks there is always possible vessel injury.
After vessel injury clot formation is important to stop
bleeding. It is estimated that time needed for stable clot
formation is 8 hours, and this time should be reached be-
fore maximum anticoagulant activity of administered
anticoagulant drug.
The rules based on the pharmacokinetics can be sum-
marized as follows:
1. The first dose of the anticoagulant after a central
nerve block must be administered so to ensure an in-
terval of at least 8 hours between the end of surgery
and the peak plasma level of the drug.
2. The removal of a epidural catheter must be delayed by
an interval of at least two half-lives have elapsed for
the anticoagulant being used. This is because only 25
% of the anticoagulant activity will remain after two
half-lives and waiting longer than two half-lives has a
diminishing effect on any further decrease. The resid-
ual drug activity provides a reasonable balance be-
tween the risk of haemorrhagic complications and the
risk of thrombosis.
3. The safety interval between the removal of catheter
and the next anticoagulant administration must be
delayed by a time calculated from the hemostasis time
minus the peak plasma level of the drug (the longer
peak level, the shorter the time delay).
Fondaparinux
Fondaparinux is licensed for the prevention of venous
thromboembolism (VTE) in high risk patients. It is an
injectable synthetic pentasaccharide that acts indirectly
on factor Xa via antithrombin III. Fondaparinux was ap-
proved in December 2001 and FDA released fondapa-
rinux (Arixtra) with a block box warning similar to that
of the LMWHs and heparinoids.
It is highly selective, without any effect on factor IIa
(thrombin) or platelets. Its half life is 17–20 hours in nor-
mal individuals allowing for single-daily dose, but may
be significantly prolonged in patients with renal impair-
ment. In the perioperative setting fondaparinux treat-
ment should start 6 hours postoperatively, provided sur-
gical haemostasis is secured. Kidney function sholud be
monitored. Investigators reported a spinal hematoma
among the initial dose-ranging study. No additional spi-
nal hematoma was reported in the combined series of
3600 patients who underwent spinal or epidural anae-
sthesisin in combination with fondaparinux thrombo-
prophylaxis.
Nevertheless, its use in orthopedic patients has re-
mained somewhat limited. This may be because of con-
cerns over possible increased bleeding risk relative to
some other anticoagulants. Because of bleeding risk, fon-
daparinux is contraindicated in patients who weigh less
than 50 kg, and its package insert recommends caution
when it is used in the elderly due to an increased risk of
bleeding in patients aged 65 or older. Additionally, the
Pentasaccharide in Major Knee Surgery (PENTAMAKS)
study found fondaparinux to be associated with a signifi-
cantly higher incidence of major bleeding compared with
enoxaparin (2.1% vs 0.2%; p=0.006) in major knee sur-
gery, although it was superior to enoxaparin in prevent-
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ing VTE. Other possible reasons for slow adoption of
fondaparinux include its long half-life, which results in a
sustained antithrombotic effect, its lack of easy revers-
ibility, and a contraindication in patients with renal in-
sufficiency.
Anaesthetic management of the patient
receiving Fondaparinux
The actual risk of spinal hematoma with fondaprinux
is unknown. Consensus statement are based on the sus-
tained and irreversible antithrombotic effect, early post-
operative dosing and the spinal hematoma reported dur-
ing initial clinical trials.
 The first dose is administered no less than 6 hours af-
ter completion of central nerve blockade (CNB).
 In patients with ongoing treatment, fondaparinux
should be witheld at least 36 hours before the initia-
tion of a CNB.
Until further clinical experience is available, perfor-
mance od neuraxial technique sholud occur under con-
ditions used in clinical trials (single-needle pass, atrau-
matic needle placement, avoidance of indwelling neura-
xial catheters). If this is not feasible, an alternate method
of prophylaxis should be considered.
Rivaroxaban
Rivaroxaban is a potent selective and reversible oral
activated factor Xa inhibitor, with an oral biovaliability
of 80 %. It is approved for use in Europe and Canada for
tromboprophylaxis after total hip or knee replacement.
There are many clinical trials comparing rivaroxaban
with LMWH (enoxaparin) in patients with joint re-
placement. According these studies rivaroxaban have su-
periority with less incidence or thromboembolic events
and simplicity of oral administration. Current studies are
assessing the role of rivaroxaban in treating thrombosis
and prophylaxis of VTE in medical patients and in pre-
venting arterial thromboembolism in both high-risk
atrial fibrillation and acute coronary syndrome patients.
Rivaroxaban has predictable pharmacokinetics with
high oral biovaliability and a rapid onset of action. The
absorbtion after oral intake is nearly 100%. The peak
level is reached at 2–4 hours, and its half life is 5–9 hours.
Inhibition is maintained for 12 hours. After administra-
tion approximately 66 % undergoes metabolic degrada-
tion, with half being eliminated renally and the other
half through fecal route. The final 33 % undergoes direct
renal excretion mainly through active renal secretion.
Elimination half life is 9 hours in healthy subjects and is
prolonged to 13 hours in elderly with decline in renal
function (dose adjustment is needed in patients with re-
nal insufficiency). For patients in whom rivaroxaban is
indicated, no coagulation monitoring is required.
In patients with hip or knee arthroplasty the recom-
mended dose is an oral once-daily 10 mg tablet. The first
dose should be given 6–8 hours after wound closure. It is
not necessary to adjust dose in the presence of mild or se-
vere renal impairment (creatine clearance 15–80 mL/
min) and it is contraindicated in hepatic desease with
coagulopathy and clinical bleeding risk, and should be
used with caution in patients with moderate hepatic im-
pairment.
Anaesthetic management of the patient
receiving Rivaroxaban
 Folowing a CNB, there should be a delay of on less
than 6 hours before revaroxaban treatment is initiated
(24 hours if the procedure has been traumatic or
bloody)
 In patients with ongoing treatment, there should be a
delay of no less than 18 hours between the last dose
and the initiation of a CNB (manufacturers recom-
mendation).
 Spinal anaesthesia: when spinal anaesthesia has been
performed, rivaroxaban can be given at 6–8 hours af-
ter wound closure as thromboprophylaxis. If a trau-
matic puncture occurs the first dose should be delayed
for 24 hours.
 Epidural anaesthesia: it is possible to perform epi-
dural anaesthesia with a permanent catheter for post-
operative analgesia. The first dose with catheter in
place will be given 6–10 hours after the end of surgery.
Between the administration of drug and the removal
of catheter it is necessary at least 18 hours. In elderly
patients, due to prolonged half-life this time shold be
longer and it could be established in 22–26 hours. The
minimal interval between catheter removal and next
dose of rivaroxaban should be 4 hours.
Regional anaesthesia was performed in more than
half of patients included in clinical trials but no informa-
tion regarding needle placement or catheter introduction
was included. Although there have been no reported spi-
nal hematomas, the lack of information regarding specif-
ics or regional anaesthesia and the prolonged half life
warrants a cautious approach.
Dabigatran
Direct thrombin inhibitors are new class of anticoag-
ulants used primarily in the treatment of heparin-in-
duced thrombocytopenia and percutaneous coronary in-
terventions. Dabigtran etexilate is prodrug that inhibits
both free and clot-bound thrombin. The drug is ab-
sorbed from the gastrointestinal tract with bioavaliabity
of 5 %. After absorbtion is converted to active metabolite,
dabigatran. Plasma level peak at 2 hours. The half life is 8
hours after single dose and up to 17 hours after multiple
doses. Because 80 % of the drug is excreted unchanged by
the kidneys, it is contraindicated in patients with renal
failure. Its elimination is dependent on kidney function,
and is contraindicated in patients with severe renal im-
pairment (creatine clearence < 30 mL/min). In patients
with creatine clereance 30–50 mL/min and in patients
over 75 years the daily dose should be reduced to 150 mg.
It is not recommended in patients with elevated liver en-
zymes more than two times the upper limit of normal.
There is no specific antidote, but reversal of anticoag-
ulant effect is theoretically possible with administration
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of recombinant factor VIIa, although this has not been
atempted clinically. In the case of bleeding the best op-
tion could be to administer prothrombin concentrates or
fresh frozen plasma depending on te modification of
clotting test.
Dabigatran has been licensed for thromboprophylaxis
in patients undegoing hip or knee arthroplasty and is un-
der evaluation in ongoing trials for prevention of stroke
in patients with atrial fibrillation, acute VTE treatment
and secondary prevention of cardiac events in patients
with acute coronary syndrome.
There are many clinical trials comparing thrombo-
embolic events in patients with joint replacement receiv-
ing dabigatran or LMWH (enoxaparin). According the-
se studies the incidence of thromboembolic events is less
with administration of dabigatran. Dose recommenda-
tions are 110 mg 1 to 4 hours after surgery, and thereafter
220 mg/day for up to 35 days. The dosing is once daily
given perorally.
Anaesthetic management of the patient
receiving Dabigatran
 The first dose of dabigatran should be given no less
than 6 hours after a CNB or catheter removal.
 The first dose should wait a minimum of 2 hours after
removal of an epidural catheter (manufacturers rec-
ommendation).
 Spinal anaesthesia: after performing spinal atrauma-
tic anaesthesia the first dose can be given at 1–4 hours
after the end of surgery. If a traumatic/hemorrhagic
puncture occurs the first dose of dabigatran should be
delayed for 24 hours.
 Epidural aneshesia: dabigatran cannot be adminis-
tered if epidural anaesthesia with insertion of perma-
nent catheter has been performed. Once a dose of the
anticoagulant has been given, the safety time between
the removal of catheter and the next administration of
drug would be 36 hours, but this practice has not been
valid anywhere.
Among published studies there was no randomisation
regarding anaesthetic technique or criteria based on the
performance of neuraxial block, including the presence
of an indwelling catheter or traumatic needle/catheter
placement. There have been no reported spinal hemato-
mas, but the lack of information regarding the specifcs of
block performance and the prolonged half-life warrants
cautious approach.
CONCLUSION
The alarmingly high incidence od spinal hematomas
reported during 1990s after introduction of LMWH for
thromboprophylaxis led to numerous national and inter-
national guidelines intented to reduce the risk of spinal
bleeding where CNBs are performed in patients given
anticoagulated drugs. The new anticoagulated drugs in-
troduced in last 10 years (fondaparinux, rivaroxaban and
dabigatran) are administered with great caution in pa-
tients receiving spinal/epidural anaesthesia. Pharmaco-
logic properties are very important for safe management
of these drugs and CNBs. Elimination half time, peak ef-
fect, time needed for cloth formation must be calculated
before performing spinal/epidural anaesthesia and cath-
eter placement. With this cautious approach the danger
of spinal bleeding is minimum.There are many studies
performed in patients with joint replacement and no case
of spinal hematoma is reported. Unfortunatelly there are
no prospective randomised studies analysing regional
anaesthesia and new anticoagulated drugs, and further
investigations are necessary before definitive recommen-
dations of performing spinal/epidural anaesthesia and
catheter manipulation will be proposed.
Reported studies confirmed safe use of regional anae-
sthesia procedures in patients taken anticoagulated drugs.
It should be remmembred that decision to perform re-
gional anaesthesia in the patients receiving new anti-
thrombotic drugs should be made on an individual basis
weighing risk of neuraxial bleeding with the benefits of
regional anaesthesia. The procedures of regional anaes-
thesia must be performed according to the guidelines of
blockade in anticoagulated patients. With these guide-
lines the benefits of regional anaesthesia in orthopedic
procedures will improve clinical results and patients sat-
isfactions with minimal risks regarding possible compli-
cations of concomitant use of anticoagulated drugs and
neuraxial anaesthesia.
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